Cargando…
TRPC6 inhibitor (BI 764198) to reduce risk and severity of ARDS due to COVID-19: a phase II randomised controlled trial
BACKGROUND: Despite the availability of COVID-19 vaccinations, there remains a need to investigate treatments to reduce the risk or severity of potentially fatal complications of COVID-19, such as acute respiratory distress syndrome (ARDS). This study evaluated the efficacy and safety of the transie...
Autores principales: | Ware, Lorraine B, Soleymanlou, Nima, McAuley, Danny Francis, Estrada, Vicente, Diaz, George A, Lacamera, Peter, Kaste, Renee, Choi, Wansuk, Gupta, Abhya, Welte, Tobias |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10359525/ https://www.ncbi.nlm.nih.gov/pubmed/37024277 http://dx.doi.org/10.1136/thorax-2022-219668 |
Ejemplares similares
-
Evidence for chemokine synergy during neutrophil migration in ARDS
por: Williams, Andrew E, et al.
Publicado: (2017) -
New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality
por: Ewig, S, et al.
Publicado: (2009) -
Viruses causing lower respiratory symptoms in young children: findings from the ORChID birth cohort
por: Sarna, Mohinder, et al.
Publicado: (2018) -
Prevalence of swallow, communication, voice and cognitive compromise following hospitalisation for COVID-19: the PHOSP-COVID analysis
por: Dawson, Camilla, et al.
Publicado: (2023) -
Increasing burden of community-acquired pneumonia leading to hospitalisation, 1998–2014
por: Quan, T Phuong, et al.
Publicado: (2016)